2. Search Result
Search Result
Results for "

Staphylococcus aureus gyrase

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0506
    Nadifloxacin
    1 Publications Verification

    OPC7251

    		 Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related Infection Inflammation/Immunology
    Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
    Nadifloxacin
  • HY-N7066
    Difloxacin hydrochloride

    A-56619 hydrochloride

    		 Bacterial DNA/RNA Synthesis Infection
    Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and *Staphylococcus aureus* infections .
    Difloxacin hydrochloride
  • HY-N1341
    Roseoside

    		HCV HCV Protease DNA/RNA Synthesis Bacterial Infection
    Roseoside is an inhibitor of DNA gyrase and HAV 3C protease, and also inhibits HCV NS5A/B replicase in human systems with an IC50 of 20 μM. Roseoside binds to the active site of enzymes and stabilizes the interaction by forming hydrogen bonds with key amino acid residues. Roseoside inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, and interferes with HCV RNA replication in vitro by inhibiting HCV NS5A/B replicase (IC50=20 μM). Roseoside shows no cytotoxicity and serves as a research tool for studies related to bacterial infections, candidiasis, HAV and HCV .
    Roseoside
  • HY-108988
    Albicidin

    		Antibiotic Bacterial Topoisomerase DNA/RNA Synthesis Infection
    Albicidin is a peptide antibiotic with phytotoxic activity. Albicidin potently inhibits bacterial and plant DNA gyrase at nanomolar concentrations, blocks DNA replication, and exhibits excellent antibacterial efficacy against multidrug-resistant bacteria. Albicidin possesses bactericidal activity against Gram-positive and Gram-negative microorganisms, and acts as a virulence factor for the systemic plant infection by Xanthomonas albilineans. Albicidin can be used in studies related to bacterial infections and sugarcane leaf blight .
    Albicidin
  • HY-115990
    Topoisomerase IV inhibitor 1

    		Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
    Topoisomerase IV inhibitor 1
  • HY-156014
    qsl-304

    		DNA/RNA Synthesis Infection
    qsl-304 is a DNA gyrase B inhibitor. qsl-304 is an antibacterial agent, with an IC50 of 31.23 mg/mL against the Staphylococcus aureus sa-P2003 .
    qsl-304
  • HY-W264454
    Antibacterial agent 303

    		Bacterial Infection
    Antibacterial agent 303 (compound 3) is an antibacterial agent exhibiting potent antibacterial activity against MDR strains, with MICs of 10 and 100 µg/mL against Pseudomonas aeruginosa MDR1 and Staphylococcus aureus MDR strains, respectively. Antibacterial agent 303 displays strong binding affinities to E. coli DNA gyrase and Candida albicans lanosterol 14α-demethylase. Antibacterial agent 303 can be used for drug-resistant infections research .
    Antibacterial agent 303
  • HY-178949
    MRSA antibiotic 3

    		Antibiotic Bacterial DNA/RNA Synthesis Infection
    MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
    MRSA antibiotic 3
  • HY-172264
    XT17

    		Antibiotic Bacterial DNA/RNA Synthesis Infection
    XT17 is an anthrone compound with broad-spectrum antibacterial activity. It exerts its antibacterial effect by disrupting the cell wall and inhibiting DNA synthesis. XT17 exhibits weak hemolytic activity, low cytotoxicity against mammalian cell lines, and a low frequency of drug resistance. Meanwhile, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies have confirmed that XT17 can form a stable complex with bacterial gyrase. XT17 can be used in the research of the anti - infection field .
    XT17
  • HY-125424
    AM8191 hydrochloride

    		Bacterial Inflammation/Immunology
    AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
    AM8191 hydrochloride
  • HY-115991
    Topoisomerase IV inhibitor 2

    		Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 5d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
    Topoisomerase IV inhibitor 2
  • HY-170567
    DNA gyrase/Topo IV-IN-1

    		Topoisomerase Bacterial Antibiotic Infection
    DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC50 of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC50 values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .
    DNA gyrase/Topo IV-IN-1
  • HY-168511
    DNA Gyrase-IN-13

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-13 (compound 1b) is a DNA Gyrase inhibitor. DNA Gyrase-IN-13 has antibacterial activity. DNA Gyrase-IN-13 has an IC50 value of 1.81 μM for Staphylococcus aureus DNA gyrase .
    DNA Gyrase-IN-13
  • HY-149534
    DNA Gyrase-IN-9

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-9 (compound 4j) is an antibacterial agent that targets DNA gyrase. The MIC to inhibit Gram bacteria is 0.5-2 μg/mL, and the MBC to kill Gram bacteria is 2-8 μg/mL. DNA Gyrase-IN-9 inhibits DNA gyrase in Staphylococcus aureus with IC50=6.29 μg/mL .
    DNA Gyrase-IN-9
  • HY-147948
    DNA Gyrase-IN-4

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-4 (compound 8p) is a potent DNA gyrase inhibitor, with an IC50 of 0.13 μM. DNA Gyrase-IN-4 shows excellent antibacterial activity against Staphylococcus aureus, Listeria monocytogenes, Salmonella and Escherichia coli, with MIC values of 0.05, 0.05, 0.05, and 8 μg/mL, respectively .
    DNA Gyrase-IN-4
  • HY-146403
    Antibacterial agent 98

    		Bacterial Infection
    Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus) .
    Antibacterial agent 98
  • HY-161788
    DNA Gyrase-IN-11

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-11 (Compound 23Be) is an inhibitor for protein synthesis (IC50 is 0.74 μM) and DNA replication. DNA Gyrase-IN-11 inhibits DNA gyrase, that inhibits E. coli DNA supercoiling with IC50 of 11.9 μM. DNA Gyrase-IN-11 exhibits antibacterial efficacy, that inhibits Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Staphylococcus aureus, with MICs of 0.008-0.25 μg/mL .
    DNA Gyrase-IN-11
  • HY-172109
    DNA Gyrase-IN-15

    		DNA/RNA Synthesis Infection
    DNA Gyrase-IN-15 (Compound 11) is an antimicrobial agent and inhibitor of DHPS and DNA gyrase, with IC50s of 1.73 and 0.07 µM, respectively. DNA Gyrase-IN-15 shows antimicrobial activity against Enterococcus faecalis (MIC of 15.62 µg/mL), Acinetobacter baumannii, Enterobacter species (MIC of 7.81 µg/mL), Pseudomonas aeruginosa, Klebsiella pneumoniae and Staphylococcus aureus. DNA Gyrase-IN-15 also shows antibiofilm activity against Enterococcus faecalis .
    DNA Gyrase-IN-15
  • HY-14780
    Viquidacin

    NXL 101

    		 Antibiotic Topoisomerase DNA/RNA Synthesis Bacterial Infection
    Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .
    Viquidacin
  • HY-163104
    Antibacterial agent 169

    		Bacterial Infection
    Antibacterial agent 169 (Compound 28) is a pyrrolamide-type GyrB/ParE inhibitor with antibacterial activity. Antibacterial agent 169 has an inhibitory effect on Gyrase and Topo IV of Staphylococcus aureus, with IC50 values of 49 nmol/L and 1.513 μmol/L respectively .
    Antibacterial agent 169
  • HY-161937
    Antibacterial agent 236

    		Topoisomerase Bacterial Infection
    Antibacterial agent 236 (Compound 4l) is an orally active inhibitor for DNA gyrase and topoisomerase IV (IC50 is 3.2 and 300 nM in Staphylococcus aureus), and exhibits board-spectrum antibacterial activity. Antibacterial agent 236 exhibits good pharmacokinetic properties in mice .
    Antibacterial agent 236
  • HY-116926
    Deoxynybomycin

    		Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Apoptosis Infection Cancer
    Deoxynybomycin is an antibiotic, that can be isolated from Streptomyces, and antibacterial activity against Staphylococcus aureus. Deoxynybomycin is the inhibitor for DNA gyrase and Topoisomerase I. Deoxynybomycin induces expression of p21/WAF1, exhibits cytotoxicity and induces apoptosis in cancer cells Saos-2, TMK-1, and THP-1 .
    Deoxynybomycin
  • HY-182074
    DNA Gyrase-IN-18

    		Bacterial Topoisomerase Infection
    DNA Gyrase-IN-18 (Compound 6B) is a DNA Gyrase inhibitor and Antibacterial agent. DNA Gyrase-IN-18 significantly inhibits the supercoiling activity of DNA Gyrase. DNA Gyrase-IN-18 inhibits biofilm formation by *Staphylococcus aureus*. DNA Gyrase-IN-18 exhibits excellent antibacterial activity, with a MIC of 0.125 μg/mL against Staphylococcus aureus and a MIC of 0.5 μg/mL against Mycobacterium tuberculosis .
    DNA Gyrase-IN-18
  • HY-113718
    DS21412020

    		Bacterial Topoisomerase DNA/RNA Synthesis Infection
    DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin (HY-121544)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics .
    DS21412020
  • HY-181819
    Antibacterial agent 327

    		Bacterial Topoisomerase Infection
    Antibacterial agent 327 (Compound 6f) is an Antibacterial agent. Antibacterial agent 327 potently inhibits the supercoiling activity of Staphylococcus aureus DNA gyrase with an IC50 of 0.28 μM. It also inhibits the ATPase activities of DNA gyrase and Topoisomerase IV, as well as the decatenation activity of Topoisomerase IV (IC50: 0.43 μM, 0.73 μM, and 2.31 μM, respectively). Antibacterial agent 327 potently inhibits Clostridioides difficile and methicillin-resistant Staphylococcus aureus (HY-121544), with an MIC of 0.78 μg/mL for both. Antibacterial agent 327 inhibits Escherichia coli with an MIC50 of 0.78 μg/mL .
    Antibacterial agent 327
  • HY-B0506R
    Nadifloxacin (Standard)

    OPC7251 (Standard)

    		 Reference Standards Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related Infection Inflammation/Immunology
    Nadifloxacin (Standard) is the analytical standard of Nadifloxacin (HY-B0506). This product is intended for research and analytical applications. Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
    Nadifloxacin (Standard)
  • HY-B0506S1
    Nadifloxacin-d5

    OPC7251-d5

    		 Isotope-Labeled Compounds Antibiotic Bacterial DNA/RNA Synthesis Interleukin Related Infection Inflammation/Immunology
    Nadifloxacin-d5 (OPC7251-d5) is deuterium labeled Nadifloxacin (HY-B0506). Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
    Nadifloxacin-d5
  • HY-B0395E
    (1S,2R,7S)-Sitafloxacin

    (1S,2R,7S)-DU-6859a; DU-6856

    		 Antibiotic Bacterial Topoisomerase Infection
    (1S,2R,7S)-Sitafloxacin (DU-6856) is an enantiomer of Sitafloxacin (HY-B0395). (1S,2R,7S)-Sitafloxacin is a topoisomerase inhibitor. (1S,2R,7S)-Sitafloxacin is an antibiotic. (1S,2R,7S)-Sitafloxacin has inhibitory activity against Escherichia coli DNA gyrase (IC50 0.18 μg/mL) and Staphylococcus aureus topoisomerase IV. (1S,2R,7S)-Sitafloxacin has antibacterial activity and can be used in the study of various bacterial infections .
    (1S,2R,7S)-Sitafloxacin
  • HY-181820
    Topoisomerase IV-IN-3

    		Topoisomerase DNA Glycosylase Bacterial Infection
    Topoisomerase IV-IN-3 is a Staphylococcus aureus Topoisomerase IV inhibitor, DNA gyrase inhibitor and antibacterial agent. Topoisomerase IV-IN-3 has IC50 values of 1.32 μM and 0.48 μM against topoisomerase IV, and 0.88 μM and 0.54 μM against DNA gyrase. Topoisomerase IV-IN-3 inhibits decatenation, ATPase, and supercoiling activities of its target enzymes. Topoisomerase IV-IN-3 exerts antibacterial activity against Gram-positive and Gram-negative bacterial strains. Topoisomerase IV-IN-3 exhibits low cytotoxicity toward human fibroblast cells. Topoisomerase IV-IN-3 can be used for the research of bacterial infections .
    Topoisomerase IV-IN-3
  • HY-107044
    DK 507k

    		Bacterial Topoisomerase Infection
    DK 507k is an orally active 8-methoxyquinolone Antibacterial agent. DK 507k targets DNA gyrase subunit A (GyrA) and modulates the function of GyrA. DK 507k inhibits the growth of various Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. DK 507k eliminates Penicillin-tolerant Streptococcus pneumoniae from the lungs of mice. DK 507k can be used in research related to sepsis and *Streptococcus pneumoniae* pneumonia .
    DK 507k
  • HY-126258
    IMP-1700

    		Bacterial DNA/RNA Synthesis Infection
    IMP-1700 is a potent DNA damage potentiator and antibacterial agent. IMP-1700 inhibits the bacterial SOS response to DNA damage. IMP-1700 potently sensitizes MRSA to Ciprofloxacin (HY-B0356) with an EC50 of 5.9 nM. IMP-1700 inhibits the growth of E. coli K-12 BW25113, S. aureus SH1000 and MRSA USA300 JE2 .
    IMP-1700
  • HY-116558
    E-4441

    		Bacterial Infection
    E-4441 is an orally active Antibacterial agent. E-4441 exerts broad-spectrum in vitro antibacterial activity against Gram-positive bacteria and aerobic bacteria. E-4441 exhibits protective effects against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa infections. E-4441 can be used in the research of systemic bacterial infections (Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa infections) .
    E-4441
  • HY-183712
    Antibacterial agent 345

    		Bacterial DNA/RNA Synthesis Drug Derivative Infection
    Antibacterial agent 345 is a Ciprofloxacin (HY-B0356)-lipophilic derivative and is an antibacterial agent. Antibacterial agent 345 inhibits DNA gyrase and inhibits bacterial DNA replication and transcription. Antibacterial agent 345 inhibits bacterial biofilm formation. Antibacterial agent 345 can be used for the research of bacterial infections, such as Pseudomonas aeruginosa infection .
    Antibacterial agent 345

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: